Immunosyn Releases Wound Healing Photographs From the First Phase 'Proof of Concept Trial' in Europe for Treatment of Diabetic U
February 26 2008 - 9:00AM
PR Newswire (US)
LA JOLLA, Calif., Feb. 26 /PRNewswire-FirstCall/ -- Immunosyn
Corporation (OTC:IMYN) (BULLETIN BOARD: IMYN) received permission
from Argyll Biotechnologies, LLC to release before and after wound
healing photographs resulting from subcutaneous injections of the
biopharmaceutical SF-1019 from the first phase of a formal "Proof
of Concept Trial" which has been successfully completed in Europe
for treatment of Diabetic Ulcers with SF-1019. (Photo:
http://www.newscom.com/cgi-bin/prnh/20080226/LATU104) The primary
purpose of the "Proof of Concept Trial" is to further evaluate the
safety and efficacy of SF-1019 in the treatment of Diabetic
Ulceration and its effect on Diabetic Polyneuropathy in Type 1
Diabetes Mellitus by both subcutaneous injection and by topical
application. The first phase, which is now complete, involved an
extremely small cohort of patients. "Seldom is it possible to
demonstrate the efficacy of a biopharmaceutical such as SF-1019 in
a media that people can actually see," said Stephen D. Ferrone,
President and CEO of Immunosyn. "Photographic evidence such as this
is indeed significant." The images seen below as well as additional
images are also available for viewing at
http://www.immunosyn.com/du-beforeandafter.html. A specialized grid
referenced Polaroid camera was used for photographic documentation
in order to prevent digital manipulation and to substantiate
authenticity of the images. "This first very important phase in the
development of SF-1019, which was undertaken at a European venue by
Argyll Biotechnologies, has indicated that SF-1019 promotes wound
healing and almost certainly induces growth factors. When
systemically delivered (subcutaneously), SF-1019 has shown the
resolution of long standing chronic lesions which is very
impressive," stated Professor Angus Dalgleish, MBBS, BSc, MD, FRCP,
RACP, FRCPath, FMedSci, Chief Scientist and Consultant Medical
Officer for Argyll Biotechnologies, LLC. Professor Dalgleish is
also a member of Immunosyn's Scientific Advisory Board. "Because of
the positive results, which both the independent clinical team and
I have observed during the first phase of the 'Proof of Concept
Trial' and with the absence of any adverse side effects, the trial
will go forward to the next phase and will be expanded to cover a
wider group of patients," advised Clinical Director for Argyll
Biotechnologies, David Maizels, MD, MSc, MRCS, LRCP. It is expected
that the next phase will be completed during the first half of 2008
and if successful larger-scale independently-managed formal
Clinical Trials, leading to a licensed product in Europe, will take
place shortly thereafter at a world-renowned specialist wound
healing clinic. According to the International Diabetes Federation
(IDF), globally, an approximated 246 million people have Diabetes
Mellitus, of which one in six will develop a diabetic foot ulcer.
Also according to IDF, extensive epidemiological surveys indicate
that between 40% and 70% of all lower extremity amputations are
related to diabetes and that every 30 seconds a leg is lost to
diabetes somewhere in the world. Argyll Biotechnologies, LLC is
Immunosyn's strategic partner and largest shareholder, as well as
the developer and licensor of SF-1019 for which Immunosyn has been
granted the world-wide rights to market, sell and distribute under
an exclusive license agreement. About Immunosyn Corporation La
Jolla, CA-headquartered Immunosyn Corporation (IMYN.OTC.BB) plans
to market and distribute life enhancing therapeutics. Currently,
the company has exclusive worldwide rights from its largest
shareholder, Argyll Biotechnologies, LLC, to market, sell and
distribute SF-1019, a compound that was developed from extensive
research into Biological Response Modifiers (BRMs). Argyll
Biotechnologies, LLC has initiated the process for regulatory
approval of SF-1019 in several countries and preparations for
clinical trials are underway in both the US and Europe. Research
suggests that SF-1019 has the potential to affect a number of
clinical conditions including complications from Diabetic Mellitus
such as Diabetic Neuropathy (DN) and diabetic ulcers (DU),
auto-immune disorders such as Multiple Sclerosis (MS) and
neurological disorders such as Chronic Inflammatory Demyelinating
Polyneuropathy (CIDP) and Reflex Sympathetic Dystrophy Syndrome
(RSD or RSDS). (For more information on Immunosyn and SF-1019 go to
http://www.immunosyn.com/) The above news release contains
forward-looking statements. These statements are based on
assumptions that management believes are reasonable based on
currently available information, and include statements regarding
the intent, belief or current expectations of the Company and its
management. Prospective investors are cautioned that any such
forward-looking statements are not guarantees of future
performance, and are subject to a wide range of business risks,
external factors and uncertainties. Actual results may differ
materially from those indicated by such forward-looking statements.
For additional information, please consult the Company's most
recent public filings and Annual Report on Form 10-K for its most
recent fiscal year. The Company assumes no obligation to update the
information contained in this press release, whether as a result of
new information, future events or otherwise. CONTACT: Bill
Kraus/Lisa Baker/Devon Blaine The Blaine Group 310/360-1499
310/360-1498 (FAX)
http://www.newscom.com/cgi-bin/prnh/20080226/LATU104
http://photoarchive.ap.org/ DATASOURCE: Immunosyn Corporation
CONTACT: Bill Kraus, Lisa Baker or Devon Blaine, +1-310-360-1499,
fax, +1-310-360-1498, , all of The Blaine Group, for Immunosyn
Corporation Web site: http://www.immunosyn.com/
Copyright